United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Company Stock

United Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • EVP Paul Mahon sold 8,300 United Therapeutics shares for about $4.69 million at an average price of $565.09, reducing his direct stake by 15.52% to 45,172 shares.
  • In its latest quarter, the company’s earnings per share of $5.71 missed estimates of $6.01, while revenue of $832.5 million exceeded expectations and rose 4.1% year over year.
  • United Therapeutics authorized a $2 billion share buyback, covering up to 8.3% of outstanding shares. Analysts’ average price target is $676.40, with a “Moderate Buy” consensus rating.
  • MarketBeat previews the top five stocks to own by December 1st.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $565.09, for a total transaction of $4,690,247.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company's stock, valued at $25,526,245.48. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $18.24 during trading on Thursday, reaching $559.10. 393,748 shares of the stock traded hands, compared to its average volume of 552,176. The stock has a 50-day moving average of $547.74 and a two-hundred day moving average of $538.10. United Therapeutics Corporation has a 52-week low of $455.63 and a 52-week high of $614.23. The stock has a market cap of $23.81 billion, a P/E ratio of 21.10, a price-to-earnings-growth ratio of 3.88 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts' consensus estimates of $6.01 by ($0.30). The firm had revenue of $832.50 million during the quarter, compared to analysts' expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics's revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.16 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 25.08 earnings per share for the current year.

United Therapeutics declared that its board has authorized a stock buyback program on Thursday, October 22nd that allows the company to repurchase $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. Jefferies Financial Group reaffirmed a "buy" rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Leerink Partners lifted their price objective on United Therapeutics from $685.00 to $725.00 and gave the stock an "outperform" rating in a report on Monday, October 19th. UBS Group set a $725.00 target price on United Therapeutics in a research report on Monday, October 19th. Raymond James Financial set a $720.00 target price on shares of United Therapeutics in a research note on Wednesday, November 4th. Finally, Royal Bank Of Canada raised their price target on shares of United Therapeutics from $697.00 to $725.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $676.40.

View Our Latest Stock Analysis on United Therapeutics

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Callan Family Office LLC bought a new stake in United Therapeutics in the 2nd quarter worth approximately $1,217,000. Andra AP fonden raised its holdings in shares of United Therapeutics by 33.5% during the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company's stock worth $18,912,000 after acquiring an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $3,359,000. Partners Capital Investment Group LLP bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $1,691,000. Finally, Palo Alto Investors LP bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $33,911,514. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines